These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18270046)

  • 1. A step toward optimization of cancer therapeutics. Physiologically based modeling of circadian control on cell proliferation.
    Clairambault J
    IEEE Eng Med Biol Mag; 2008; 27(1):20-4. PubMed ID: 18270046
    [No Abstract]   [Full Text] [Related]  

  • 2. The circadian timing system: a coordinator of life processes: chronobiological investigations. Implications for the rhythmic delivery of cancer therapeutics.
    Lévi FA
    IEEE Eng Med Biol Mag; 2008; 27(1):17-9. PubMed ID: 18270045
    [No Abstract]   [Full Text] [Related]  

  • 3. Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model.
    Florian JA; Eiseman JL; Parker RS
    Comput Biol Med; 2008 Mar; 38(3):339-47. PubMed ID: 18222419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
    Clairambault J
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
    Lévi F; Altinok A; Clairambault J; Goldbeter A
    Philos Trans A Math Phys Eng Sci; 2008 Oct; 366(1880):3575-98. PubMed ID: 18644767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A qualitative approach to cell growth modeling and simulation for cancer chemotherapy.
    Gaglio S; Giacomini M; Nicolini C; Ruggiero C
    IEEE Trans Biomed Eng; 1991 Apr; 38(4):386-9. PubMed ID: 1855803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics.
    Lévi F; Filipski E; Iurisci I; Li XM; Innominato P
    Cold Spring Harb Symp Quant Biol; 2007; 72():465-75. PubMed ID: 18419306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cell cycle automaton model for probing circadian patterns of anticancer drug delivery.
    Altinok A; Lévi F; Goldbeter A
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1036-53. PubMed ID: 17692993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cells: a step toward the cure.
    Boman BM; Wicha MS
    J Clin Oncol; 2008 Jun; 26(17):2795-9. PubMed ID: 18539956
    [No Abstract]   [Full Text] [Related]  

  • 10. Delay equations modeling the effects of phase-specific drugs and immunotherapy on proliferating tumor cells.
    Barbarossa MV; Kuttler C; Zinsl J
    Math Biosci Eng; 2012 Apr; 9(2):241-57. PubMed ID: 22901063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronobiology in oncology.
    Haus E
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):3-5. PubMed ID: 19100918
    [No Abstract]   [Full Text] [Related]  

  • 12. Estimation of likely cancer cure using first- and second-order product densities of population balance models.
    Sherer E; Hannemann RE; Rundell A; Ramkrishna D
    Ann Biomed Eng; 2007 Jun; 35(6):903-15. PubMed ID: 17440813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modeling and simulation framework to support early clinical drug development decisions in oncology.
    Bruno R; Lu JF; Sun YN; Claret L
    J Clin Pharmacol; 2011 Jan; 51(1):6-8. PubMed ID: 20628172
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer chronotherapeutics: experimental, theoretical, and clinical aspects.
    Ortiz-Tudela E; Mteyrek A; Ballesta A; Innominato PF; Lévi F
    Handb Exp Pharmacol; 2013; (217):261-88. PubMed ID: 23604483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer and the circadian clock: has the time finally come?
    Hede K
    J Natl Cancer Inst; 2009 Apr; 101(8):550-3. PubMed ID: 19351915
    [No Abstract]   [Full Text] [Related]  

  • 16. [The circadian-timing system: a determinant of drug activity and a target of anticancer treatments].
    Lévi F
    Ann Pharm Fr; 2008 Jun; 66(3):175-84. PubMed ID: 18706346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling.
    Altinok A; Lévi F; Goldbeter A
    Eur J Pharm Sci; 2009 Jan; 36(1):20-38. PubMed ID: 19041394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy may be delivered based on an integrated view of tumour dynamics.
    Ribba B; You B; Tod M; Girard P; Tranchand B; Trillet-Lenoir V; Freyer G
    IET Syst Biol; 2009 May; 3(3):180-90. PubMed ID: 19449978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian cancer pharmacodynamics.
    Hrushesky WJ
    Ann Ist Super Sanita; 1993; 29(4):705-10. PubMed ID: 7985931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dynamic circadian system patients under chimiotherapy].
    Beau J; Iurisci I; Beau T; Lévi F
    Pathol Biol (Paris); 2007; 55(3-4):171-5. PubMed ID: 17412521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.